Panelsequenzierung in der Kopf-Hals-Onkologie am Beispiel von sinunasalen und Speicheldrüsenmalignomen

[1]  A. Agaimy.  SWI/SNF-deficient Malignancies: Optimal Candidates for Immune-oncological Therapy? , 2022, Advances in anatomic pathology.

[2]  A. Agaimy.  Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022: SWI/SNF-deficient Sinonasal Neoplasms: An Overview , 2022, Head and Neck Pathology.

[3]  A. Franchi,et al.  Towards a Molecular Classification of Sinonasal Carcinomas: Clinical Implications and Opportunities , 2022, Cancers.

[4]  OUP accepted manuscript , 2022, The Oncologist.

[5]  A. Dimmler,et al.  Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report , 2021, Diagnostic Pathology.

[6]  G. Lilly,et al.  Induction Chemotherapy for Orbit Preservation in Sinonasal Squamous Cell Carcinoma , 2021, Journal of Neurological Surgery Reports.

[7]  S. Knapp,et al.  Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy , 2021, Oncogene.

[8]  A. Hartmann,et al.  ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas , 2021, The American journal of surgical pathology.

[9]  A. Franchi,et al.  High-grade Transformation/Dedifferentiation in Salivary Gland Carcinomas: Occurrence Across Subtypes and Clinical Significance. , 2021, Advances in anatomic pathology.

[10]  J. Nör,et al.  Systemic therapies for salivary gland adenoid cystic carcinoma. , 2021, American journal of cancer research.

[11]  Larissa Di Villeneuve,et al.  Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease , 2020, Frontiers in Oncology.

[12]  K. Magliocca,et al.  Recurrent Loss of SMARCA4 in Sinonasal Teratocarcinosarcoma , 2020, The American journal of surgical pathology.

[13]  W. Faquin,et al.  Immune checkpoint inhibitors in sinonasal squamous cell carcinoma. , 2020, Oral oncology.

[14]  S. Basu,et al.  Combined 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option , 2020, The Journal of Nuclear Medicine Technology.

[15]  S. Basu,et al.  Gratifying results with combined Chemo-PRRT (177Lu-DOTATATE and platinum-based chemotherapy) in Recurrent Metastatic Sinonasal Neuroendocrine Carcinoma with high uptake on both 68Ga-DOTATATE and 18F-FDG PET-CT: a Promising Therapeutic Option. , 2020, Journal of nuclear medicine technology.

[16]  B. Dickson,et al.  Salivary Gland Cancer in the Era of Routine Next-Generation Sequencing , 2020, Head and Neck Pathology.

[17]  L. Mariani,et al.  Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life , 2020, Cancer.

[18]  J. Bishop,et al.  Soft Tissue Special Issue: Adamantinoma-Like Ewing Sarcoma of the Head and Neck: A Practical Review of a Challenging Emerging Entity , 2020, Head and Neck Pathology.

[19]  J. Schalken,et al.  68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study , 2020, Theranostics.

[20]  V. Lund,et al.  Sinonasal Undifferentiated Carcinoma (SNUC): From an Entity to Morphologic Pattern and Back Again-A Historical Perspective. , 2019, Advances in anatomic pathology.

[21]  L. Mariani,et al.  Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract , 2019, Head & neck.

[22]  William A. Pastor,et al.  SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer , 2019, Nature Communications.

[23]  M. Amit,et al.  Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Fisher,et al.  NUT Carcinoma of the Salivary Glands: Clinicopathologic and Molecular Analysis of 3 Cases and a Survey of NUT Expression in Salivary Gland Carcinomas , 2018, The American journal of surgical pathology.

[25]  J. Gilbert,et al.  Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma , 2018, American journal of clinical oncology.

[26]  N. Rupp,et al.  Molecular Profiling of Mammary Analog Secretory Carcinoma Revealed a Subset of Tumors Harboring a Novel ETV6-RET Translocation: Report of 10 Cases , 2018, The American journal of surgical pathology.

[27]  A. Llombart‐Bosch,et al.  Sinonasal Tract Alveolar Rhabdomyosarcoma in Adults: A Clinicopathologic and Immunophenotypic Study of Fifty-Two Cases with Emphasis on Epithelial Immunoreactivity , 2018, Head and Neck Pathology.

[28]  Hyunseok Kang,et al.  Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. , 2017, Oral oncology.

[29]  M. Ahn,et al.  Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14‐01) , 2017, Cancer.

[30]  J. Hainsworth,et al.  Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway. , 2017 .

[31]  V. Miller,et al.  Significant and durable clinical benefit from trastuzumab in 2 patients with HER2‐amplified salivary gland cancer and a review of the literature , 2017, Head & neck.

[32]  U. Pastorino,et al.  Lung metastasectomy in adenoid cystic cancer: Is it worth it? , 2017, Oral oncology.

[33]  J. Yoon,et al.  Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells , 2017, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[34]  Tiffany Y. Chen,et al.  HPV-related Multiphenotypic Sinonasal Carcinoma: An Expanded Series of 49 Cases of the Tumor Formerly Known as HPV-related Carcinoma With Adenoid Cystic Carcinoma-like Features , 2017, The American journal of surgical pathology.

[35]  L. Mariani,et al.  A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. , 2016, European journal of cancer.

[36]  C. Antonescu,et al.  A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  G. Floris,et al.  Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients , 2016, Acta clinica Belgica.

[38]  C. Antonescu,et al.  Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma. , 2016 .

[39]  D. Hayes,et al.  Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Sung-Bae Kim,et al.  Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma , 2015, Cancer.

[41]  Simion I. Chiosea,et al.  Molecular Characterization of Apocrine Salivary Duct Carcinoma , 2015, The American journal of surgical pathology.

[42]  J. Homer,et al.  Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck , 2015, Head & neck.

[43]  C. French.  The Importance of Diagnosing NUT Midline Carcinoma , 2013, Head and Neck Pathology.

[44]  J. Reis-Filho,et al.  Salivary duct carcinomas can be classified into luminal androgen receptor‐positive, HER2 and basal‐like phenotypes * , 2012, Histopathology.

[45]  T. Ettl,et al.  The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. , 2012, Oral oncology.

[46]  L. Siu,et al.  A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  W. Ryder,et al.  Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. , 2011, The British journal of oral & maxillofacial surgery.

[48]  B. Perez-Ordonez,et al.  Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity , 2010, The American journal of surgical pathology.

[49]  M. Seshadri,et al.  A prospective, randomised, placebo-controlled trial of postoperative oral steroid in allergic fungal sinusitis , 2010, European Archives of Oto-Rhino-Laryngology.

[50]  L. Mariani,et al.  Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. , 2009, Oral oncology.

[51]  C. French,et al.  Carcinomas of the Upper Aerodigestive Tract With Rearrangement of the Nuclear Protein of the Testis (NUT) Gene (NUT Midline Carcinomas) , 2009, Advances in anatomic pathology.

[52]  R. Demicheli,et al.  Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  L. Licitra,et al.  Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients , 1991, Cancer.

[54]  R. Sarasin.  Carcinomas of the upper aerodigestive tract. , 1948 .